Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Out-of-Pocket Cost of Oral TKIs Linked to Poor Lung Cancer Survival

Key clinical point: Higher out-of-pocket costs for oral tyrosine kinase inhibitors were linked to inferior survival in patients with advanced, biomarker-positive non–small cell lung cancer.

Major finding: Patients in the high-cost quartile were 2.31 times as likely to die as patients in the lower quartiles, according to results of a multivariable analysis.

Study details: A retrospective study including data on 106 patients with EGFR- and ALK-positive stage IV non–small cell lung cancer in the Washington Surveillance, Epidemiology, and End Results registry who had at least one oral tyrosine kinase inhibitors prescription.

Disclosures: Funding for the study came from the National Institutes of Health. Dr. Goulart reported disclosures related to Flatiron Health (travel, accommodations, and expenses).

Citation:

Goulart BHL et al. QCS 2019, Abstract 3.